Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-03-20
1999-12-14
Stockton, Laura L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
5142245, 5142292, 514285, 514365, 514394, 514418, 514419, 514448, A61K 3140, A61K 31535, A61K 3154, A61K 3138
Patent
active
060018666
DESCRIPTION:
BRIEF SUMMARY
This invention concerns a method for treating and preventing inflammation or atherosclerosis in mammals by administering a compound which is an inhibitor of the enzyme 15-lipoxygenase (15-LO).
BACKGROUND OF THE INVENTION
Atherosclerosis is a multifactorial disease characterized by excessive intracellular lipid deposition in macrophages, leading to formation of foam cells. The accumulation of lipid-loaded foam cells in the subendothelial space leads to formation of fatty streaks, which are the early atherosclerotic lesions. Oxidative modification of lipids, specifically low-density lipoprotein, has been implicated as a major process in foam-cell formation.
Lipoxygenases are nonheme iron-containing enzymes that catalyze the oxygenation of certain polyunsaturated fatty acids such as lipoproteins. Several different lipoxygenase enzymes are known, each having a characteristic oxidation action. One specific lipoxygenase, namely 15-LO, has been detected in atherosclerotic lesions in mammals, specifically rabbit and man. The enzyme, in addition to its role in oxidative modification of lipoproteins, is important in the inflammatory reaction in the atherosclerotic lesion. Indeed, 15-LO has been shown to be induced in human monocytes by the cytokin IL-4, which is known to be implicated in the inflammatory process.
Another class of lipoxygenase enzymes is 5-lipoxygenase (5-LO). While this enzyme causes oxidation of unsaturated fatty acids, it primarily is responsible for inserting oxygen on position 5 of arachidonic acid. Other lipoxygenases are known; one of the most common and abundant being 12-lipoxygenase (12-LO).
We have now found that inhibitors of 15-LO are especially useful to prevent and treat inflammation and atherosclerosis. While there are several lipoxygenase enzymes, specific inhibition of 15-LO is critical in the inflammatory and atherosclerosis process. All that is required according to this invention is to administer a 15-LO inhibitor, and especially one that is a specific 15-LO inhibitor.
Several classes of organic compounds are 15-LO inhibitors.
Tetracyclic indole and benzopyranoindole compounds are potent 15-LO inhibitors. U.S. Pat. No. 3,388,133 describes benz[b]indolo[2,3-d]-thiopyrano and pyrylium salts as antibacterial and antifungal agents. U.S. Pat. No. 4,132,714 describes a process for making chromenoindoles, which are said to be useful as color-forming agents. U.S. Pat. No. 4,797,495 discloses a wide variety of benzocarbazoles which are said to be antitumor agents. Similarly, benzimidazoles are well known as antiviral agents. U.S. Pat. No. 4,293,558 describes various 1-thiazolinyl-2-aminobenzimidazoles, and U.S. Pat. No. 4,243,813 describes 1-sulfonyl-benzimidazoles. None of those compounds have been described as inhibitors of 15-LO, and none have been utilized in treating inflammation or atherosclerosis. All of these compounds are 15-LO inhibitors and can be employed in the method of this invention.
We have now discovered that compounds which are effective inhibitors of 15-LO are useful in treating and preventing inflammation and atherosclerosis.
SUMMARY OF THE INVENTION
This invention provides a method for treating and preventing inflammation or atherosclerosis in mammals comprising administering an effective amount of a 15-LO inhibitor. The invention preferably employs a specific 15-LO inhibitor. In a preferred embodiment, the 15-LO inhibitor is a benzopyranoindole or related compound as described in U.S. Pat. Nos. 3,388,133, 4,132,714, and 4,797,495, which are incorporated herein by reference. Especially preferred 15-LO inhibitors have Formula I ##STR3## wherein: R.sup.1 is hydrogen or C.sub.1 -C.sub.6 alkyl; -C.sub.6 alkyl, nitro, halo, CN, OR.sup.6, NR.sup.6 R.sup.7, --CO.sub.2 R.sup.6, CONR.sup.6 R.sup.7, CH.sub.2 OR.sup.6, or CH.sub.2 NR.sup.6 R.sup.7, and R.sup.2 and R.sup.3, and R.sup.4 and R.sup.5, when attached to adjacent ring atoms, can be --(CH.sub.2).sub.3 or 4 --; alkyl, phenyl or benzyl, and when taken together with the nitrogen to which they are attached, R.sup.6 an
REFERENCES:
patent: 3388133 (1968-06-01), Young et al.
patent: 3956295 (1976-05-01), Biere et al.
patent: 4123439 (1978-10-01), Balli et al.
patent: 4132714 (1979-01-01), Petitpierre
patent: 4238233 (1980-12-01), Yamada et al.
patent: 4608390 (1986-08-01), Summers, Jr.
patent: 4623661 (1986-11-01), Summers, Jr.
patent: 4797495 (1989-01-01), Bair
patent: 4873257 (1989-10-01), Mobilio
patent: 4873258 (1989-10-01), Bair
patent: 4876246 (1989-10-01), Guindon et al.
patent: 4939133 (1990-07-01), Connor et al.
patent: 4939145 (1990-07-01), Lau et al.
patent: 4952597 (1990-08-01), Bair
Belkner et al., Oxygenation of lipoproteins, by mammalian lipoxygenases, Eur. J. Biochem, vol. 213 (1993), pp. 251-261.
Yia-Herttuala et al., Gene Express. in Macrophage-rich Human Atherosclerotic Lesions, J. Clin. Inv., vol. 87 (1991) pp. 1146-1152.
P.N. Preston et al., Benzimidazoles & Cong. Tricy. Cmpds., Part 1, Interscience, pp. 149-157 (Year not Available).
Gleason et al., Characterization & inhibition of 15-lipoxygenase in human monocytes: comparison with soybean 15-lipoxygenase, Am. J. Physiology, vol. 268 (1995) ppC1301-C1307.
Harats et al., A Possible Role for 15-Lipoxygenase in Atherogenesis, TCM vol. 5, No. 1(1995)pp.29-36.
Schewe et al., Do 15-lipoxygen. have a comm. biolog. role?Elsevier Sci. Pub.,UK,Oct.(1995) pp.369-373.
Conrad et al., Specific inflammatory cytokines regulate the expression of human monocyte 15-lipoxygenase, Proc. Natl. Acad. Sci. USA, vol. 89 Jan. (1992) pp.217-221.
Cornicelli Joseph A.
Tait Bradley D.
Trivedi Bharat K.
Ashbrook Charles W.
Stockton Laura L.
Warner-Lambert & Company
LandOfFree
Method for treating and preventing inflammation and atherosclero does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating and preventing inflammation and atherosclero, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating and preventing inflammation and atherosclero will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-863866